Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) ended the last trading day at $4.29. Company weekly volatility is calculated as 6.33% and price to cash ratio as 1.76. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) showed a weekly performance of 1.90%.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that abstracts for two posters addressing preclinical results with the company’s pan-caspase inhibitors, have been accepted for presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco November 13-17, 2015.
CGI Group, Inc. (NYSE:GIB) ended the last trading day at $36.86. Company weekly volatility is calculated as 1.48% and price to cash ratio as 52.33. CGI Group, Inc. (NYSE:GIB) showed a weekly performance of -0.70%.
Zacks upgraded shares of CGI Technologies and CGI Group, Inc. (NYSE:GIB) from a sell rating to a hold rating in a report released on Wednesday, MarketBeat.com reports.
Micron Technology, Inc. (NASDAQ:MU) caters to the Technology space. It has a net profit margin of 21.30% and weekly performance is 1.87%. On the last day of trading company shares ended up at $18.50. Micron Technology, Inc. (NASDAQ:MU) distance from 50-day simple moving average (SMA50) is 11.75%.
On 5 October, Micron Technology, Inc. (NASDAQ:MU) poised for a second session of strong gains, after reporting better-than-expected quarterly results last week. The chip maker posted fiscal fourth-quarter earnings of 37 cents a share, ahead of the 31-cent a share forecast by analysts in a FactSet survey.
The Chemours Company (NYSE:CC) shares fell -9.62% in last trading session and ended the day at $6.39. CC Gross Margin is 18.80% and its has a return on assets of 6.80%. The Chemours Company (NYSE:CC) quarterly performance is -46.42%.
On 15 October, The Chemours Company (NYSE:CC) ‘s executives said their low Global Warming Potential products could potentially eliminate 300 million tons of carbon dioxide emissions worldwide by 2025.
Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) caters to the Healthcare space. Its weekly performance is 1.56%. On the last day of trading company shares ended up at $1.30. Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) distance from 50-day simple moving average (SMA50) is -5.93%.
On 7 October, Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) announced that it has submitted an Investigational New Drug Application in the U.S. to expand recruiting for its first in class lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP).
Leave a Reply